Literature DB >> 1804007

Attenuation of antibody response to acute pyelonephritis by treatment with antibiotics.

D E Neal1, M B Kaack, G Baskin, J A Roberts.   

Abstract

While acute pyelonephritis is known to elicit an antibody response, it is also known that a patient who has had pyelonephritis once is susceptible to recurrent renal infection. Using our experimental model of pyelonephritis in the monkey, we tested whether antibiotic therapy of the acute disease would affect the antibody response. We found that it did, because antibiotic therapy beginning 72 h after bacterial inoculation attenuated the antibody response so that rechallenge 3 months later produced acute pyelonephritis and prolonged bacteriuria. The animals with untreated infection had an antibody response that lasted a sufficient period of time to prevent acute pyelonephritis after renal challenge. We have confirmed that antibody titers against P fimbriae are protective, and to a degree, this protective effect may be abrogated by antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804007      PMCID: PMC245382          DOI: 10.1128/AAC.35.11.2340

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  STUDIES OF URINARY TRACT INFECTIONS IN INFANCY AND CHILDHOOD. I. ANTIBODY RESPONSE IN DIFFERENT TYPES OF URINARY TRACT INFECTIONS CAUSED BY COLIFORM BACTERIA.

Authors:  J WINBERG; H J ANDERSEN; L A HANSON; K LINCOLN
Journal:  Br Med J       Date:  1963-08-31

2.  Relation of the incubation period and the secondary immune response to lasting immunity to infectious diseases.

Authors:  C M MACLEOD
Journal:  J Immunol       Date:  1953-04       Impact factor: 5.422

3.  P-fimbriae vaccines. I. Cross reactive antibodies to heterologous P-fimbriae.

Authors:  M B Kaack; A Pere; T K Korhonen; S B Svenson; J A Roberts
Journal:  Pediatr Nephrol       Date:  1989-10       Impact factor: 3.714

4.  P-fimbriae vaccines. II. Cross reactive protection against pyelonephritis.

Authors:  J A Roberts; M B Kaack; G Baskin; T K Korhonen; S B Svenson; J Winberg
Journal:  Pediatr Nephrol       Date:  1989-10       Impact factor: 3.714

5.  Experimental pyelonephritis in the monkey. II. The prognostic value of radionuclide evaluation of the urinary tract.

Authors:  J A Roberts; G J Domingue
Journal:  Invest Urol       Date:  1975-03

Review 6.  The human antibody response to uropathogenic Escherichia coli: a review.

Authors:  I E Salit; J Hanley; L Clubb; S Fanning
Journal:  Can J Microbiol       Date:  1988-03       Impact factor: 2.419

7.  Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.

Authors:  B Pecha; D Low; P O'Hanley
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

8.  Urinary immunoglobulins in healthy individuals and children with acute pyelonephritis.

Authors:  C Svanborg Edén; R Kulhavy; S Mårild; S J Prince; J Mestecky
Journal:  Scand J Immunol       Date:  1985-04       Impact factor: 3.487

9.  Local and systemic antibody responses accompany spontaneous resolution of experimental cystitis in cynomolgus monkeys.

Authors:  W J Hopkins; D T Uehling; E Balish
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

10.  P-fimbriated Escherichia coli urinary tract infection: a clinical correlation.

Authors:  K J Dowling; J A Roberts; M B Kaack
Journal:  South Med J       Date:  1987-12       Impact factor: 0.954

View more
  1 in total

Review 1.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.